Halozyme Therapeutics completes $1.5 billion convertible notes offering

Halozyme completed a $1.5 billion offering of 1.50% convertible senior notes due 2033, generating approximately $1.47 billion in net proceeds. It will spend $187.5 million on capped calls to limit conversion dilution and approximately $652.5 million, including interest, to repurchase portions of its 2027 and 2028 convertible notes. The financing follows a strong Q2 2026 beat—non-GAAP EPS of $2.28 versus $1.81 expected and revenue of $481 million versus $401.27 million consensus—and a raised full-year outlook.

Analysis

The financing lowers near-term cash interest while extending maturities, but its economic purpose is more consequential than the coupon: it creates a sizeable acquisition and partnership-war chest after refinancing legacy converts. That raises the probability of an inorganic growth transaction within 6-12 months, which could support the multiple if management acquires royalty-bearing assets, but the market should discount any deal that substitutes lower-margin development risk for the current asset-light royalty model. The conversion threshold creates a technical pivot near $140: below it, dilution is largely deferred; above it, the capped-call protection mitigates dilution only through roughly $208, not indefinitely.

Near term, convertible-arbitrage hedging can constrain upside after a sharp run, although dealer hedging associated with the capped call may partly offset that pressure. Over 1-3 months, the key question is whether royalty guidance continues to rise independently of partner-drug milestones; a valuation built on royalty durability is vulnerable to even modest reductions in partner uptake assumptions. The more material 6-18 month risk is competitive substitution from alternative subcutaneous-delivery platforms, including Alteogen's expanding licensing footprint: each incremental large-pharma validation of a rival platform weakens Halozyme's scarcity premium even before it affects reported revenue.

Consensus appears to treat the capital raise as purely balance-sheet-positive. The contrarian view is that raising a large amount of cheap capital after a substantial rerating signals management sees a need to deploy capital to preserve growth beyond the current royalty portfolio; that is not automatically accretive. HALO remains attractive only if management demonstrates that new capital earns returns above the royalty business's high incremental margins, rather than merely preventing a future growth deceleration.

Key Decisions for Investors

• Maintain, but do not chase, a HALO long below the $140 conversion pivot; add only on a pullback toward $105-$110 or after independently verifiable upward royalty guidance. Target $140-$155 over 6-12 months; exit on a material royalty-guide cut or an acquisition priced at a premium without clear near-term accretion.
• For existing HALO equity exposure, buy 6-12 month $100/$85 put spreads to protect against post-financing multiple compression and partner-platform competition. The hedge is most valuable if HALO fails to hold roughly $105, where the market would likely reassess the growth premium rather than merely digest technical issuance.
• Use a relative-value watch: long HALO versus short ARGX only after ARGX-specific clinical or commercial momentum materially outpaces HALO royalty revisions. The thesis is that HALO has broader platform and capital-allocation optionality, but it is invalidated if VYVGART Hytrulo growth becomes the dominant driver of HALO's earnings sensitivity.
• Treat any announced acquisition as a decision point, not an automatic catalyst: add only if the transaction is funded without incremental equity dilution and management quantifies a return profile above the cost of capital. A cash-heavy deal for development-stage assets would support reducing HALO exposure despite the low-cost financing.